

REMARKS

Applicants have amended the claims as pending after entry of the Amendment filed in the present case on February 5, 2003. Claim 1 has been amended to be directed to an isolated glycoprotein that is present on stomach carcinoma cells, but not on normal cells, and includes at least one section of the amino acid primary structure of CD55 and a tumor-specific glycostructure. Support for this amendment may be found, for example, at page 3, line 25, to page 4, line 5 of Applicants' specification. New claim 43 is directed to an isolated glycoprotein that includes at least one section of the human amino acid primary structure of CD55 and a tumor-specific glycostructure, where the glycoprotein, if present on a cell and bound by an antibody that is specific for the glycostructure, results in apoptosis of the cell. Support for this amendment may be found, for example, at page 4, lines 7-11, and page 7, lines 2-14, of the specification. In addition, new claim 42 finds support, for example, in original claim 4, and new claim 44 finds support, for example, at page 5, lines 12-18, and page 19, line 17, to page 20, line 19.

Enclosed is a Petition to extend the period for submitting a reply pursuant to the Notice of Appeal filed on February 3, 2003 for two months, to and including June 3, 2003, and a check in payment of the required extension fee.


If there are any additional charges or any credits, please apply them to Deposit
Account No. 03-2095.

Respectfully submitted,

Date: June 3, 2003

Susan M. Michaud
Kristina Bieker-Brady, Ph.D.
Reg. No. 39,109 Susan M. Michaud
Reg. No. 42,885

Clark & Elbing LLP
101 Federal Street
Boston, MA 02110
Telephone: 617-428-0200
Facsimile: 617-428-7045





U.S. Serial No. 09/469,606

Version of Claims Showing Changes Made

RECEIVED
JUN 10 2003
TECH CENTER 1600/2900

Cancel claims 38 and 41.

Amend claims 1, 4, and 39, as follows.

1. (Five Times Amended) An isolated glycoprotein comprising at least one section of the human amino acid primary structure of CD55 and a tumor-specific glycostructure, [and has a molecular weight of 82kD, wherein the glycostructure reacts with monoclonal antibody SC-1] wherein said glycoprotein is present on a stomach carcinoma cell, but not on a normal cell.

4. (Three Times Amended) A process for obtaining a glycoprotein according to claim 1, comprising producing a membrane preparation from cells of the human adenocarcinoma cell line 23132, and obtaining the glycoprotein therefrom by size-exclusion [and/or anion-exchange] chromatography.

39. (Amended) The glycoprotein of claim [38] 1, wherein said glycoprotein is present on [isolatable from] human adenocarcinoma cell line 23132.

Add new claims 42-44.

42. (New) A process for obtaining a glycoprotein according to claim 1, comprising producing a membrane preparation from cells of the human adenocarcinoma cell line 23132, and obtaining the glycoprotein therefrom by anion-exchange chromatography.

43. (New) An isolated glycoprotein comprising at least one section of the human amino acid primary structure of CD55 and a tumor-specific glycostructure, wherein said glycoprotein, if present on a cell and bound by an antibody that is specific for said glycostructure, results in apoptosis of said cell.

44. (New) The glycoprotein of claim 43, wherein said glycoprotein is present on human adenocarcinoma cell line 23132.

Clean Version of All Pending Claims After Entry of the Amendment

1. (Five Times Amended) An isolated glycoprotein comprising at least one section of the human amino acid primary structure of CD55 and a tumor-specific glycostructure, wherein said glycoprotein is present on a stomach carcinoma cell, but not on a normal cell.

3. A glycoprotein according to claim 1, which, in SDS polyacrylamide-gel electrophoresis, exhibits an apparent molecular weight of 82 kD.

4. (Three Times Amended) A process for obtaining a glycoprotein according to claim 1, comprising producing a membrane preparation from cells of the human adenocarcinoma cell line 23132, and obtaining the glycoprotein therefrom by size-exclusion chromatography.

39. (Amended) The glycoprotein of claim 1, wherein said glycoprotein is present on human adenocarcinoma cell line 23132.

40. The glycoprotein of claim 1 which is naturally occurring.

42. (New) A process for obtaining a glycoprotein according to claim 1, comprising producing a membrane preparation from cells of the human adenocarcinoma cell line 23132, and obtaining the glycoprotein therefrom by anion-exchange chromatography.

43. (New) An isolated glycoprotein comprising at least one section of the human amino acid primary structure of CD55 and a tumor-specific glycostructure, wherein said glycoprotein, if present on a cell and bound by an antibody that is specific for said glycostructure, results in apoptosis of said cell.

44. (New) The glycoprotein of claim 43, wherein said glycoprotein is present on human adenocarcinoma cell line 23132.